Holen Sie sich die Stockscreener-App
6.67
0.60%
0.04
Handel nachbörslich:
6.67
Schlusskurs vom Vortag:
$6.63
Offen:
$6.77
24-Stunden-Volumen:
373.86K
Relative Volume:
0.95
Marktkapitalisierung:
$184.10M
Einnahmen:
$45.07M
Nettoeinkommen (Verlust:
$-44.49M
KGV:
-1.7949
EPS:
-3.716
Netto-Cashflow:
$-54.23M
1W Leistung:
-7.87%
1M Leistung:
-9.86%
6M Leistung:
-3.75%
1J Leistung:
+47.24%
1-Tages-Spanne:
$6.41
$6.923
1-Wochen-Bereich:
$6.41
$7.38
52-Wochen-Spanne:
$3.53
$9.62
Precision Biosciences Inc Stock (DTIL) Company Profile
Firmenname
Precision Biosciences Inc
Sektor
Branche
Telefon
919-314-5512
Adresse
302 EAST PETTIGREW STREET, DURHAM, NC
Compare DTIL vs VRTX, REGN, MRNA, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DTIL
Precision Biosciences Inc
|
6.67 | 197.90M | 45.07M | -44.49M | -54.23M | -3.716 |
VRTX
Vertex Pharmaceuticals Inc
|
516.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.45 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
158.07 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
995.77 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
196.94 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Precision Biosciences Inc Stock (DTIL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-10 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2024-04-30 | Eingeleitet | Guggenheim | Buy |
| 2022-06-17 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-06-09 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-07-27 | Fortgesetzt | BTIG Research | Buy |
| 2020-04-03 | Herabstufung | Goldman | Buy → Neutral |
| 2020-03-05 | Eingeleitet | Stifel | Buy |
| 2020-02-25 | Eingeleitet | William Blair | Outperform |
| 2019-08-09 | Eingeleitet | BTIG Research | Buy |
| 2019-07-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-22 | Eingeleitet | Barclays | Overweight |
| 2019-04-22 | Eingeleitet | Goldman | Buy |
| 2019-04-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-04-22 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Precision Biosciences Inc Aktie (DTIL) Neueste Nachrichten
Chronic Hepatitis B Market Statistics Expected to Experience Major Growth by 2034, According to DelveInsight | Gilead Sciences, GlaxoSmithKline, Ionis Pharma, Precision Biosciences, Silverback Thera - Barchart.com
CPTx appoints Matt Kane as Chief Financial Officer - GlobeNewswire Inc.
Behavioral Patterns of DTIL and Institutional Flows - Stock Traders Daily
Precision BioSciences stock gains as market cap tops 200 million USD - ad-hoc-news.de
Precision Biosciences Stock Price Forecast. Should You Buy DTIL? - StockInvest.us
Precision BioSciences Inc. (DTIL) Key Financial Ratios – Valuation, Profitability & More - Value Research
Precision BioSciences Inc. (DTIL) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
iECURE Presents Updated Clinical Data from OTC-HOPE Trial of ECUR-506 in Neonatal-Onset Ornithine Transcarbamylase Deficiency at SSIEM 2026 - Business Wire
Precision BioSciences doses first patient in DMD gene editing trial By Investing.com - Investing.com Canada
Precision BioSciences (DTIL) draws 1.1M-share Weinstein stake - Stock Titan
Precision (DTIL) Range: Posts a 2.59% Gain to $8.72 at the Close; the Current Price Sits Inside the Supplied Technical Range in the Latest ReadingLiquidity Order Flow - vinanet.vn
DTIL Looks 355.6% Overvalued on GF Value™ - GuruFocus
Precision BioSciences: Promising HBV Editing Evidence (NASDAQ:DTIL) - Seeking Alpha
Precision BioSciences Inc (DTIL) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Precision BioSciences Inc Stock Intrinsic Values - GuruFocus
Precision BioSciences Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Competitors 2026 - GuruFocus
Precision BioSciences Inc Stock Warning Signs | HAM:PBS0 - GuruFocus
Who's Buying or Selling Precision BioSciences Inc (HAM:PBS0) Stock Today? - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock Price & 30 Year Financial Data - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock Earnings Transcripts - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
HAM:PBS0 Dividend: Does Precision BioSciences Inc Pay a Dividend? - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock Price, Trades & News - GuruFocus
Precision BioSciences Inc (HAM:PBS0) Stock News, Headlines & Updates - GuruFocus
Precision BioSciences (DTIL) Rises 1.78% as Gene-Editing Stock Holds Firm Above SupportGrowth Stock Picks - vinanet.vn
Precision BioSciences (DTIL) Advances 1.78% as Gene-Editing Speculation BuildsBear Flag - vinanet.vn
DTIL Q2 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Biotech ChallengesGAAP Earnings Report - vinanet.vn
Analysts Have Lowered Expectations For Precision BioSciences, Inc. (NASDAQ:DTIL) After Its Latest Results - webull.com
Precision BioSciences (NASDAQ:DTIL) Announces Quarterly Earnings Results - MarketBeat
Precision BioSciences (NASDAQ:DTIL) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Precision BioSciences | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Precision Trading with Precision Biosciences Inc. (DTIL) Risk Zones - Stock Traders Daily
Precision BioSciences, Inc. (DTIL) stock price, news, quote and history - Yahoo Finance Singapore
DTIL Looks 315.0% Overvalued on GF Value™ - GuruFocus
Form 8K Precision BioSciences Inc For: 6 August By Investing.com - Investing.com Nigeria
Precision BioSciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Precision BioSciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Precision BioSciences Q2 net loss widens on warrant liability charge - TradingView
Precision BioSciences reports Q2 2026 net loss $32.7M; $112.4M cash supports runway through 2028 - TradingView
PRECISION BIOSCIENCES INC Q2 2026: Revenue $0 EPS $(1.26) — 10-Q Summary - tradingview.com
Precision BioSciences (NASDAQ: DTIL) books $10.8M H1 revenue and advances gene editing trials - Stock Titan
Precision Biosciences 2Q Loss/Shr $1.26 >DTIL - moomoo.com
Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Q2 EPS Forecast for Precision BioSciences Lowered by Analyst - MarketBeat
Revenue Downgrade: Here's What Analysts Forecast For Precision BioSciences, Inc. (NASDAQ:DTIL) - webull.com
Precision BioSciences Inc expected to post a loss of 79 cents a shareEarnings Preview - TradingView
Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Precision BioSciences (DTIL) - The Globe and Mail
Precision BioSciences (DTIL) Climbs 3.12% to $7.28 as Gene-Editing Support HoldsRegression Channel - vinanet.vn
H.C. Wainwright reiterates Precision BioSciences stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Precision BioSciences stock rating at buy - Investing.com
Finanzdaten der Precision Biosciences Inc-Aktie (DTIL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Precision Biosciences Inc-Aktie (DTIL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Amoroso Michael | President and CEO |
Feb 18 '26 |
Sale |
3.84 |
20,559 |
78,947 |
243,392 |
| Kelly John Alexander | Chief Financial Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
27,584 |
0 |
134,032 |
| Kelly John Alexander | Chief Financial Officer |
Feb 18 '26 |
Sale |
3.84 |
8,149 |
31,292 |
125,883 |
| Scimeca Dario | General Counsel and Secretary |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
61,382 |
| Scimeca Dario | General Counsel and Secretary |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
56,457 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 17 '26 |
Option Exercise |
0.00 |
16,667 |
0 |
126,851 |
| SMITH J. JEFFERSON | Chief Research Officer |
Feb 18 '26 |
Sale |
3.84 |
4,925 |
18,912 |
121,926 |
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):